AAPL279.22-13.95 (-4.76%) ▼|ABBV244.03+9.14 (+3.89%) ▲|ABT93.37+2.88 (+3.18%) ▲|ACN126.93-2.22 (-1.72%) ▼|ADBE196.16-0.39 (-0.20%) ▼|AMAT650.71+61.74 (+10.48%) ▲|AMD524.07+5.02 (+0.97%) ▲|AMGN356.12+4.73 (+1.34%) ▲|AMT170.24-4.22 (-2.42%) ▼|AMZN230.03-4.35 (-1.85%) ▼|AVGO380.30-1.78 (-0.47%) ▼|AXP342.89+0.33 (+0.09%) ▲|BA219.24-1.02 (-0.46%) ▼|BAC58.19+0.46 (+0.80%) ▲|BKNG178.89-2.39 (-1.32%) ▼|BLK973.76-8.84 (-0.90%) ▼|BMY55.70+0.70 (+1.26%) ▲|BNY145.22+1.66 (+1.16%) ▲|BRK-B489.56-5.25 (-1.06%) ▼|C145.59+2.00 (+1.39%) ▲|CAT1,043.24+48.79 (+4.91%) ▲|CL91.05-0.83 (-0.90%) ▼|CMCSA22.96+0.32 (+1.39%) ▲|COF203.80+3.32 (+1.65%) ▲|COP106.73-0.19 (-0.18%) ▼|COST947.22-13.75 (-1.43%) ▼|CRM151.19-1.58 (-1.03%) ▼|CSCO120.08+0.34 (+0.28%) ▲|CVS104.35+2.48 (+2.43%) ▲|CVX172.49+1.04 (+0.60%) ▲|DE622.31+21.56 (+3.59%) ▲|DHR194.95+6.08 (+3.22%) ▲|DIS98.53-2.59 (-2.56%) ▼|DUK126.97+0.44 (+0.35%) ▲|EMR144.03+2.59 (+1.83%) ▲|FDX326.11+9.28 (+2.93%) ▲|GD344.99+0.67 (+0.19%) ▲|GE372.51+6.63 (+1.81%) ▲|GEV1,091.33+33.68 (+3.18%) ▲|GILD124.43-0.72 (-0.58%) ▼|GM78.82-0.13 (-0.16%) ▼|GOOG340.52-4.51 (-1.31%) ▼|GOOGL342.49-2.79 (-0.81%) ▼|GS1,075.71-1.21 (-0.11%) ▼|HD342.69-0.18 (-0.05%) ▼|HON231.00+3.58 (+1.57%) ▲|IBM259.45-3.52 (-1.34%) ▼|INTC131.39-0.52 (-0.39%) ▼|INTU257.41-4.93 (-1.88%) ▼|ISRG401.86+0.03 (+0.01%) ▲|JNJ245.53+4.53 (+1.88%) ▲|JPM336.13+2.68 (+0.80%) ▲|KO80.28-0.33 (-0.40%) ▼|LIN524.08+8.35 (+1.62%) ▲|LLY1,125.92+8.66 (+0.77%) ▲|LMT506.24+14.60 (+2.97%) ▲|LOW220.72-0.74 (-0.33%) ▼|LRCX393.08+18.26 (+4.87%) ▲|MA495.72+1.31 (+0.27%) ▲|MCD267.28-6.60 (-2.41%) ▼|MDLZ61.84+0.10 (+0.16%) ▲|MDT80.92+0.79 (+0.98%) ▲|META547.24-10.56 (-1.89%) ▼|MMM167.25+1.34 (+0.81%) ▲|MO73.39+1.32 (+1.82%) ▲|MRK125.00+4.40 (+3.65%) ▲|MS222.13+2.27 (+1.03%) ▲|MSFT356.74-8.71 (-2.38%) ▼|MU1,216.23+168.31 (+16.06%) ▲|NEE87.67+0.05 (+0.05%) ▲|NFLX72.19+0.35 (+0.48%) ▲|NKE40.68-1.15 (-2.74%) ▼|NOW91.13-2.67 (-2.85%) ▼|NVDA195.38-3.54 (-1.78%) ▼|ORCL153.14-4.39 (-2.79%) ▼|PEP139.72-2.55 (-1.79%) ▼|PFE23.83-0.21 (-0.86%) ▼|PG148.50-3.54 (-2.33%) ▼|PLTR108.51-5.00 (-4.40%) ▼|PM179.12+1.81 (+1.02%) ▲|QCOM209.36+12.04 (+6.10%) ▲|RTX186.12+1.06 (+0.57%) ▲|SBUX103.21-0.31 (-0.30%) ▼|SCHW89.67-1.72 (-1.88%) ▼|SO95.81+0.03 (+0.03%) ▲|SPG225.87+3.72 (+1.67%) ▲|T22.55+0.18 (+0.78%) ▲|TMO505.38+13.18 (+2.68%) ▲|TMUS182.88+2.09 (+1.16%) ▲|TSLA375.04-0.43 (-0.11%) ▼|TXN312.33+9.22 (+3.04%) ▲|UBER72.72-1.13 (-1.53%) ▼|UNH414.70+8.90 (+2.19%) ▲|UNP266.77+6.81 (+2.62%) ▲|UPS108.60+2.46 (+2.32%) ▲|USB60.96+0.85 (+1.41%) ▲|V335.53+3.30 (+0.99%) ▲|VZ46.19+0.51 (+1.12%) ▲|WFC84.80+0.50 (+0.59%) ▲|WMT116.42-2.59 (-2.18%) ▼|XOM137.55+0.65 (+0.47%) ▲|AAPL279.22-13.95 (-4.76%) ▼|ABBV244.03+9.14 (+3.89%) ▲|ABT93.37+2.88 (+3.18%) ▲|ACN126.93-2.22 (-1.72%) ▼|ADBE196.16-0.39 (-0.20%) ▼|AMAT650.71+61.74 (+10.48%) ▲|AMD524.07+5.02 (+0.97%) ▲|AMGN356.12+4.73 (+1.34%) ▲|AMT170.24-4.22 (-2.42%) ▼|AMZN230.03-4.35 (-1.85%) ▼|AVGO380.30-1.78 (-0.47%) ▼|AXP342.89+0.33 (+0.09%) ▲|BA219.24-1.02 (-0.46%) ▼|BAC58.19+0.46 (+0.80%) ▲|BKNG178.89-2.39 (-1.32%) ▼|BLK973.76-8.84 (-0.90%) ▼|BMY55.70+0.70 (+1.26%) ▲|BNY145.22+1.66 (+1.16%) ▲|BRK-B489.56-5.25 (-1.06%) ▼|C145.59+2.00 (+1.39%) ▲|CAT1,043.24+48.79 (+4.91%) ▲|CL91.05-0.83 (-0.90%) ▼|CMCSA22.96+0.32 (+1.39%) ▲|COF203.80+3.32 (+1.65%) ▲|COP106.73-0.19 (-0.18%) ▼|COST947.22-13.75 (-1.43%) ▼|CRM151.19-1.58 (-1.03%) ▼|CSCO120.08+0.34 (+0.28%) ▲|CVS104.35+2.48 (+2.43%) ▲|CVX172.49+1.04 (+0.60%) ▲|DE622.31+21.56 (+3.59%) ▲|DHR194.95+6.08 (+3.22%) ▲|DIS98.53-2.59 (-2.56%) ▼|DUK126.97+0.44 (+0.35%) ▲|EMR144.03+2.59 (+1.83%) ▲|FDX326.11+9.28 (+2.93%) ▲|GD344.99+0.67 (+0.19%) ▲|GE372.51+6.63 (+1.81%) ▲|GEV1,091.33+33.68 (+3.18%) ▲|GILD124.43-0.72 (-0.58%) ▼|GM78.82-0.13 (-0.16%) ▼|GOOG340.52-4.51 (-1.31%) ▼|GOOGL342.49-2.79 (-0.81%) ▼|GS1,075.71-1.21 (-0.11%) ▼|HD342.69-0.18 (-0.05%) ▼|HON231.00+3.58 (+1.57%) ▲|IBM259.45-3.52 (-1.34%) ▼|INTC131.39-0.52 (-0.39%) ▼|INTU257.41-4.93 (-1.88%) ▼|ISRG401.86+0.03 (+0.01%) ▲|JNJ245.53+4.53 (+1.88%) ▲|JPM336.13+2.68 (+0.80%) ▲|KO80.28-0.33 (-0.40%) ▼|LIN524.08+8.35 (+1.62%) ▲|LLY1,125.92+8.66 (+0.77%) ▲|LMT506.24+14.60 (+2.97%) ▲|LOW220.72-0.74 (-0.33%) ▼|LRCX393.08+18.26 (+4.87%) ▲|MA495.72+1.31 (+0.27%) ▲|MCD267.28-6.60 (-2.41%) ▼|MDLZ61.84+0.10 (+0.16%) ▲|MDT80.92+0.79 (+0.98%) ▲|META547.24-10.56 (-1.89%) ▼|MMM167.25+1.34 (+0.81%) ▲|MO73.39+1.32 (+1.82%) ▲|MRK125.00+4.40 (+3.65%) ▲|MS222.13+2.27 (+1.03%) ▲|MSFT356.74-8.71 (-2.38%) ▼|MU1,216.23+168.31 (+16.06%) ▲|NEE87.67+0.05 (+0.05%) ▲|NFLX72.19+0.35 (+0.48%) ▲|NKE40.68-1.15 (-2.74%) ▼|NOW91.13-2.67 (-2.85%) ▼|NVDA195.38-3.54 (-1.78%) ▼|ORCL153.14-4.39 (-2.79%) ▼|PEP139.72-2.55 (-1.79%) ▼|PFE23.83-0.21 (-0.86%) ▼|PG148.50-3.54 (-2.33%) ▼|PLTR108.51-5.00 (-4.40%) ▼|PM179.12+1.81 (+1.02%) ▲|QCOM209.36+12.04 (+6.10%) ▲|RTX186.12+1.06 (+0.57%) ▲|SBUX103.21-0.31 (-0.30%) ▼|SCHW89.67-1.72 (-1.88%) ▼|SO95.81+0.03 (+0.03%) ▲|SPG225.87+3.72 (+1.67%) ▲|T22.55+0.18 (+0.78%) ▲|TMO505.38+13.18 (+2.68%) ▲|TMUS182.88+2.09 (+1.16%) ▲|TSLA375.04-0.43 (-0.11%) ▼|TXN312.33+9.22 (+3.04%) ▲|UBER72.72-1.13 (-1.53%) ▼|UNH414.70+8.90 (+2.19%) ▲|UNP266.77+6.81 (+2.62%) ▲|UPS108.60+2.46 (+2.32%) ▲|USB60.96+0.85 (+1.41%) ▲|V335.53+3.30 (+0.99%) ▲|VZ46.19+0.51 (+1.12%) ▲|WFC84.80+0.50 (+0.59%) ▲|WMT116.42-2.59 (-2.18%) ▼|XOM137.55+0.65 (+0.47%) ▲|
28.3 C
New York
Thursday, June 25, 2026

Tag: Corporate

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

JEF INVESTIGATION: Robbins Geller Rudman & Dowd LLP Launches Investigation into Jefferies Financial Group, Inc. and Encourages Investors and Potential Witnesses to Contact Law...

We are investigating whether Jefferies Financial Group Inc. & certain of its top executives made materially false &/or misleading statements to investors.

Think Together Awards 2026 Beyond Think Together Scholarships to Ten High School Seniors Across the State

Each recipient received $3,000 to support their future higher education goals.SANTA ANA, Calif., June 5, 2026 /PRNewswire/ -- Think Together, California's largest nonprofit expanded...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors it Has Filed a Complaint to Recover Losses Suffered by Purchasers of Verra Mobility Corporation Common...

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

Yuno Provides Corporate Update as It Advances Toward Launch, Expands Leadership Team with Talent from Binance, and Positions for Global Prediction Market Growth

Yuno provided a corporate update ahead of launch, highlighting leadership growth, product progress, and global expansion plans.

HELE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Helen of Troy Limited. Class Action Lawsuit

Robbins LLP is Investigating Allegations that Helen of Troy Limited (HELE) Misled Investors Regarding the Ability of Project Pegasus to Improve Efficiency

BMI Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in Badger Meter, Inc. Class Action Lawsuit

Robbins LLP is Investigating Allegations that Badger Meter, Inc. (BMI) Concealed Weakening Demand and Deteriorating Near-Term Order Trends

Corgi Launches Suite of Six Fixed Income ETFs on Cboe BZX, Capping a Week of 50 Fund Launches

Corgi lists CGOV, CBIL, CUST, CIEI, CIVG, and CHYG - offering Treasury and corporate bond exposure across the yield curve at an expense ratio...

Vireo Growth Inc. Completes Acquisition of Bridgewell Agribusiness LLC and Plans to Acquire Dispensaries in Nevada and Maryland

Vireo Growth Inc. completes acquisition of Bridgewell Agribusiness LLC and plans to acquire dispensaries in Nevada and Maryland.

Caliber Announces CFO Transition

SCOTTSDALE, Ariz., June 05, 2026 (GLOBE NEWSWIRE) -- Caliber (Nasdaq: CWD), a diversified real estate and digital asset management platform, today announced that Jade Leung will step down as Chief Financial Officer to pursue a new opportunity, capping an eleven-year tenure during which he built Caliber’s finance organization and helped lead the Company through its initial public offering. Mr. Leung will support an orderly transition. The change is not the result of any disagreement with the Company on any matter relating to its operations, accounting policies, practices, or financial reporting. Caliber reaffirms the full-year 2026 guidance issued on its first quarter 2026 earnings call, and the transition does not affect the Company’s strategy or financial outlook.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCorporate